{"id":3286,"date":"2026-07-01T16:22:32","date_gmt":"2026-07-01T16:22:32","guid":{"rendered":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/?p=3286"},"modified":"2026-07-01T16:22:32","modified_gmt":"2026-07-01T16:22:32","slug":"lundbeck-to-share-new-migraine-research-at-upcoming-medical-conference-in-geneva","status":"publish","type":"post","link":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/lundbeck-to-share-new-migraine-research-at-upcoming-medical-conference-in-geneva\/","title":{"rendered":"Lundbeck to Share New Migraine Research at Upcoming Medical Conference in Geneva"},"content":{"rendered":"

The pharmaceutical company Lundbeck will present new findings about migraine<\/a> treatments at the European Academy of Neurology Congress 2026, held from June 27th to 30th in Geneva, Switzerland. They will showcase five presentations highlighting their current and future migraine prevention strategies, including new research on two different medications: eptinezumab and bocunebart.<\/p>\n

The presentations on eptinezumab will focus on how it helps people with chronic migraine in ways beyond just reducing headache<\/a> days. These include looking at how it affects the use of pain relief<\/a> medications, mental health, and productivity at work.<\/p>\n

A special late-breaking presentation on bocunebart will discuss how this investigational drug works by targeting a specific pathway in the body (called the PACAP pathway) that may help prevent migraines in people who haven\u2019t responded well to other preventive treatments. Dr. Andrew Blumenfeld, a migraine specialis<\/a>t from Cedars Sinai in Los Angeles, will present the findings from the PROCEED study, saying: \u201cThis research adds to the growing scientific knowledge about how blocking the PACAP pathway could be a new way to help people with migraines who still struggle with their symptoms despite using other preventive treatments.\u201d<\/p>\n

Lundbeck will also share new results from two other studies on eptinezumab: the phase 3 SUNRISE trial and the phase 4 RESOLUTION trial. These results will look at how eptinezumab improves the overall burden of migraine, including its effects on daily functioning, mental health, and quality of life.<\/p>\n

Three of the RESOLUTION study presentations will focus on adults with chronic migraine who also frequently overuse pain relief medications. These presentations will examine how migraine affects people across different European countries, how the use of pain relief medications changes over time, and how migraine impacts symptoms of anxiety and depression<\/a>.<\/p>\n

The SUNRISE study analysis will explore how eptinezumab helps improve workplace productivity and daily activities for people with migraine in Asia and Europe.<\/p>\n

Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck, explained why these findings are important: \u201cMigraine isn\u2019t just about how many headache days a person has. For many, it affects their entire life, including work, relationships, and mental health. Unfortunately, these impacts aren\u2019t always fully captured in standard ways of measuring treatment success. At this conference, we\u2019re sharing data that better reflects the full impact of migraine and how our treatments can help. We\u2019re also excited to share our progress in understanding how bocunebart, our investigational drug, works by targeting the PACAP pathway. Together, these efforts show Lundbeck\u2019s dedication to improving brain health and finding better solutions for conditions like migraine where current treatments aren\u2019t enough.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

The pharmaceutical company Lundbeck will present new findings about migraine treatments at the European Academy of Neurology Congress 2026, held […]<\/p>\n","protected":false},"author":0,"featured_media":3287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[543],"tags":[],"class_list":["post-3286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-news"],"_links":{"self":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/comments?post=3286"}],"version-history":[{"count":1,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3286\/revisions"}],"predecessor-version":[{"id":3292,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/posts\/3286\/revisions\/3292"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media\/3287"}],"wp:attachment":[{"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/media?parent=3286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/categories?post=3286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allesleypharmacy.co.uk\/pharmacy\/wp-json\/wp\/v2\/tags?post=3286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}